Chinese guidelines for the diagnosis and treatment of human immunodeficiency virus infection/acquired immunodeficiency syndrome (2024 edition).

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

13 citing papers in PubMed.

1. Comparative Performance of AI Models and Clinicians in Evidence-Based Cardiovascular Disease Management for People Living With HIV: Comparative Study.Journal of medical Internet research · 2026
   Article
2. Effectiveness of pegylated interferon-α combined with antiretroviral therapy on HIV reservoir clearance in acute HIV infection: study protocol for a randomised controlled trial at a tertiary infectious disease hospital in Beijing, China.BMJ open · 2026
   Article
3. Functional cure of infants with HBeAg-positive chronic hepatitis B receiving antiviral treatment: Case series.Infectious diseases & immunity · 2026
   Article
4. Five-Year Immune Recovery After ART Initiation Among PLWH Aged ≥15 Years with Baseline Immunosuppression - China, 2013-2024.China CDC weekly · 2026
   Article
5. Prevalence and transmission of pretreatment drug resistance and acquired drug resistance among people living with HIV-1 in Chongqing, China, 2014-2024.Frontiers in public health · 2026
   Article
6. Real-world experience of Dolutegravir/Lamivudine for rapid initiation of antiretroviral therapy among treatment-naïve HIV-1-infected adults in China: a multicenter retrospective study.Frontiers in medicine · 2026
   Article
7. 24-month outcomes after switching to Dolutegravir/Lamivudine in people living with HIV and HBcAb positivity at the Beijing Ditan Hospital in China.Annals of medicine · 2025
   Article
8. The efficacy and safety of doravirine/lamivudine/tenofovir disoproxil fumarate in treatment-naïve and treatment-experienced patients with HIV.Annals of medicine · 2025
   Article
9. Impact on clinical biomarkers, immune recovery, and HIV reservoir dynamics of switching to EVG/c/FTC/TAF versus maintaining a non-INSTI-based regimen in virologically suppressed individuals.Infectious diseases & immunity · 2025
   Article
10. [Chinese expert consensus on the diagnosis and treatment of human immunodeficiency virus infection related diffuse large B cell lymphoma (2025)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025
    Article
11. Unlocking the Keys to Swift HIV Treatment: A Qualitative Exploration of Rapid Antiretroviral Therapy Initiation Among People Living with HIV in China.Patient preference and adherence · 2025
    Article
12. Efficacy and safety of doravirine/lamivudine/tenofovir disoproxil fumarate in HIV treatment: a real-world single-center study in China.Frontiers in medicine · 2025
    Article
13. Nutritional risk and HbA1c as critical risk factors and predictors of opportunistic infections in HIV-DM comorbid patients: a retrospective cross-sectional study.Frontiers in endocrinology · 2024
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as